RRI.CO.ID, Jakarta - The Indonesian Ministry of Health has officially partnered with the Japanese global biopharmaceutical company Takeda to build a Plasma Derivative Drug Product (PODP) ecosystem in Indonesia. This collaboration was marked by the Ministry of Health granting Takeda a plasma fractionation permit, marking the first upstream-downstream plasma ecosystem development initiative in Southeast Asia.

Indonesia's Minister of Health, Budi Gunadi Sadikin, emphasized that this strategic partnership represents a concrete step by the government to ensure independence and sustainable access to essential therapies for the community. "Through close collaboration with a trusted global partner like Takeda, Indonesia will be able to accelerate the development of a more resilient and future-ready healthcare system," Budi stated in a press release issued in Jakarta on July 13, 2026.

Initially, Takeda will invest up to US$30 million (approximately Rp539 billion) for a two-year initial development phase. This investment will be allocated to establish several plasma banks in Indonesia, scheduled to begin operations in 2027 as part of Takeda's BioLife plasma bank network.

While the domestic manufacturing facility is still undergoing a feasibility assessment, plasma collected in Indonesia will be fractionated through Takeda's global manufacturing network, with a commitment to prioritizing domestic needs. In parallel, Takeda is also reviewing regulatory compliance to establish a state-of-the-art plasma-derived therapy factory in the country.

This step comes amid growing global demand for Plasma-Derived Therapies (PODP). Currently, Indonesia and most ASEAN countries still face challenges in accessing therapy due to low rates of underdiagnosis and limited public awareness of medical conditions requiring PODP.

Minister of Investment and Downstream Development/Head of the Investment Coordinating Board (BKPM), Rosan P. Roeslani, stated that this collaboration is a long-term investment that brings opportunities for technology transfer, national human resource development, and job creation. "This partnership not only strengthens the healthcare ecosystem but also supports the ambition to make Indonesia a regional hub for healthcare innovation and advanced drug manufacturing," he said.

Ramy Riad, President of Takeda Plasma-Derived Therapies, expressed his appreciation for the expanded collaboration. He said Takeda is committed to leveraging its global expertise in plasma science to support Indonesia's long-term healthcare goals, including creating new, highly skilled jobs for local healthcare workers and laboratory technicians.